chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 66.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia
Clinical narrative: Roving severe joint pain; This is a spontaneous report from a contactable consumer, the patient. A 66-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: E/9267) via unspecified route of administration in the left arm on 28Feb2021 at 11:00 (at the age of 66-years-old) as a single dose for Covid-19 immunisation. Medical history included HBP (high blood pressure) and cholesterol. Concomitant medications were not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 02Mar2021, patient experienced roving severe joint pain. The patient did not receive any treatment for the adverse event. The events resulted in doctor or other healthcare professional office/clinic. The clinical outcome of the event roving severe joint pain was not recovered at the time of report. No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Lymph node pain, Pain, Pain in extremity, Pyrexia
Clinical narrative: Arm ache; aches; fever; lymph ache (in armpit); This is a spontaneous report from a non-contactable consumer, the patient. A 45-years- old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: ER8733) via an unspecified route of administration in the right arm on 26Mar2021 at 09:00 AM (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. Concomitant medications included ibuprofen (MANUFACTURER UNKNOWN) and paracetamol (TYLENOL) for unknown indication from an unknown date. The patient had no known allergies to medications, food or other products. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EN6199), via an unspecified route of administration in the left arm on 05Mar2021 at 01:15 PM (at the age of 45-years-old) as a single dose for COVID-19 immunisation. The patient had not received any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 27Mar2021, the patient experienced arm ache, lymph ache in armpit, fever and aches. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported event. The clinical outcome of arm ache, lymph ache in armpit, fever and aches was recovered on unknown date.   No follow-up attempts are needed. No further information is expected.
Age: 77.0
Sex: F
Vaccine: COVID19
Symptoms: Lip swelling, Mouth swelling, SARS-CoV-2 test
Clinical narrative: Major swell lips; Major swell mouth; This is a spontaneous report from a non-contactable consumer, the patient. A 77-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration on 29Mar2021 at 08:15 (at the age of 77-years old) in left arm as a single dose for COVID-19 immunisation. Medical history was reported as unknown. No allergies to medications, food, or other products. Concomitant mediation was reported as unknown. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination the patient was tested for COVID-19 and the result was unknown. On 29Mar2021 at 08:15, the patient experienced lip swelling and mouth swelling. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic treatment received for the events was reported as unknown. The clinical outcome of the events of lip swelling and mouth swelling was not recovered at the time this report.   Information about lot/batch number cannot be obtained. No further information is expected.
Age: 28.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Pain
Clinical narrative: body aches; tiredness; This is a spontaneous report from a non-contactable consumer, the patient. A 28-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE; Lot number: ER2613) via an unspecified route of administration in the left arm on 27Mar2021 at 13:30 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient had no known allergies to medications, food or other products. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE; Lot number: EN6205) via an unspecified route of administration in the left arm on 06Mar2021 at 12:00 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. The patient had not received any other vaccines within four weeks prior to the COVID vaccine. On 28Mar2021 at 15:00, after 14.5 hours of vaccination, the patient experienced body aches and tiredness. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of adverse events. The clinical outcome of the events body aches and tiredness were recovered on an unknown date in Mar2021 at the time of this report.   No follow-up attempts are needed. No further information is expected
Age: 50.0
Sex: M
Vaccine: COVID19
Symptoms: Implant site pain
Clinical narrative: Hernia mesh implant inguinal started becoming sore after second shot; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 19Feb2021 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. The relevant medical history included hypertension (HTN), asthma, penicillin (PCN) allergy and allergies (unspecified). The concomitant medications included olmesartan medoxomil (BENICAR), nebivolol hydrochloride (BYSTOLIC) and triamterene (MANUFACTURER UNKNOWN) all taken from unknown dates for unspecified indications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. The patient had not received any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient had hernia mesh implant inguinal that had become sore after the second shot on 22Feb2021 and was still hurting at the time of reporting. The patient did not receive any treatment for the reported event. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event implant site pain was not resolved at the time of reporting.   No follow-up attempts are needed; information about lot number cannot be obtained.
Age: 43.0
Sex: M
Vaccine: COVID19
Symptoms: Rash erythematous
Clinical narrative: red rashes on my forearms and chest; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old male patient received his first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP6955), via an unspecified route of administration in the left arm on 24Mar2021 at 15:00 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had a history of allergy to penicillin. The patient did not receive any other medications within two weeks of COVID-19 vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient was not diagnosed with COVID-19 prior to the vaccination. The patient had not been tested for COVID-19, since the vaccination. On 25Ma2021 at 16:30, the patient had experienced red rashes on his body especially on forearms and chest on the day after vaccination. He did not notice this until the next day of vaccination. Prominently those red rashes occurred multiple times during the day. They remained prominent for 30 to 40 minutes after which they had subsided. He also noticed that they also occurred after he ate something, but he did not change anything as far as his food was concerned. He had the same food that he was had before getting vaccinated. There were no changes in food. The patient did not receive any treatment for the adverse event. Adverse event did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. The clinical outcome of the event red rash was resolved with lasting effects on an unknown date in Mar2021.  No follow-up attempts are needed. No further information is expected.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Headache, Paraesthesia, Vertigo
Clinical narrative: Knee pain; Headache; Arm and Forehead Tingling; Room spinning; This is a spontaneous report received from a non-contactable consumer, the patient. A 57-year-old female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: er2613), via an unspecified route of administration on 22Mar2021 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medication were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 23Mar2021, the patient experienced room spinning, knee pain, headache, arm and forehead tingling. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events room spinning, knee pain, headache, arm and forehead tingling were not recovered.   No follow-up attempts are needed. No further information is expected.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Fatigue, Headache, Nausea, Tinnitus
Clinical narrative: Nausea; vomiting; Headache; Tinnitus; Weakness; lassitude; This is a spontaneous report from a contactable consumer, the patient. A 70-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6206) via an unspecified route of administration in the left arm on 21Mar2021 at 14:30 (at the age of 70-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had a history of allergy to opiates (intolerance to opiates). The patient did not take any concomitant medications. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On 22Mar2021 at 00:30, the patient experienced nausea, vomiting that lasted for several hours, headache lasted until following morning, tinnitus, weakness and lassitude lasted approximately for 24 hours. The patient did not receive any treatment for the reported events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events nausea, vomiting, headache, tinnitus, weakness and lassitude were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Vomiting
Clinical narrative: Nausea; vomiting; Headache; Tinnitus; Weakness; lassitude; This is a spontaneous report from a contactable consumer, the patient. A 70-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6206) via an unspecified route of administration in the left arm on 21Mar2021 at 14:30 (at the age of 70-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had a history of allergy to opiates (intolerance to opiates). The patient did not take any concomitant medications. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On 22Mar2021 at 00:30, the patient experienced nausea, vomiting that lasted for several hours, headache lasted until following morning, tinnitus, weakness and lassitude lasted approximately for 24 hours. The patient did not receive any treatment for the reported events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events nausea, vomiting, headache, tinnitus, weakness and lassitude were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Migraine, Pain in extremity
Clinical narrative: This is a spontaneous report from a contactable other healthcare professional, the patient. A 50-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER2613) via unspecified route of administration in the left arm on 19Mar2021 at 14:00 (at the age of 50-years-old), as a single dose for COVID-19 immunization. Medical history and concomitant medications were reported as none. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Since the vaccination, the patient had not been tested for COVID-19. On 20Mar2021, the day after injection, the patient experienced, soreness in arm, headache and fatigue and one week and one day after injection the patient experienced migraine headache. The adverse events resulted in an emergency room visit or department urgent care visit and treatment was received for the adverse events. The clinical outcomes of soreness in arm, headache, fatigue and migraine were unknown, at this time of report. No follow-up attempts are needed. No further information is expected.
Age: 51.0
Sex: M
Vaccine: COVID19
Symptoms: Body temperature, Dizziness, Fatigue, Nausea, Pyrexia
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 51-year-old, male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 30Mar2021 at 09:00 (age at vaccination 51-year-old) as single dose for COVID-19 immunization. Medical history included high blood pressure, sleep apnea and COVID-19. The patient had history of allergy to bone. Concomitant medications included losartan (MANUFACTURER UNKNOWN), meloxicam (MANUFACTURER UNKNOWN), advair inhaler (MANUFACTURER UNKNOWN) for an unknown indication and from an unknown date. Prior to vaccination the patient was diagnosed with COVID-19; Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 30Mar2021 at 22:00, the patient experienced dizziness, fever (101.9), tiredness, nausea and ringing in ears. No therapeutic measures were taken for the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event dizziness, fever, tiredness, nausea and ringing in ears were resolving. No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 51.0
Sex: M
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 51-year-old, male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 30Mar2021 at 09:00 (age at vaccination 51-year-old) as single dose for COVID-19 immunization. Medical history included high blood pressure, sleep apnea and COVID-19. The patient had history of allergy to bone. Concomitant medications included losartan (MANUFACTURER UNKNOWN), meloxicam (MANUFACTURER UNKNOWN), advair inhaler (MANUFACTURER UNKNOWN) for an unknown indication and from an unknown date. Prior to vaccination the patient was diagnosed with COVID-19; Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 30Mar2021 at 22:00, the patient experienced dizziness, fever (101.9), tiredness, nausea and ringing in ears. No therapeutic measures were taken for the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event dizziness, fever, tiredness, nausea and ringing in ears were resolving. No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia, Hypoaesthesia oral
Clinical narrative: This is a spontaneous report from a non-contactable consumer (patient). A 24-year-old female patient received first dose of BNT162B2 via an unspecified route of administration, administered in arm left on 19Mar2021 13:30 (age at 24 years old, Batch/Lot number was not reported) as single dose for COVID-19 immunization. The patient had peanuts, shellfish, shrimp allergies. Medical history also included asthma, autoimmune issues. The patient was not diagnosed with COVID-19 prior to vaccination and the patient did not test for COVID-19 since the vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Concomitant medications included loratadine (CLARITIN); Vitamin D nos (VITAMIN D); Vitamin B12 nos (VITAMIN B12). About 20 minutes after vaccination (19Mar2021 13:45), the patient experienced a loss of feeling in mouth and lips. This occurred intermittently over the next three days. Four days after the injection on 23Mar2021, the numbness spread to entire face and to extremities. The sensation was akin to getting an anesthetic like novocaine which was just starting to wear off. The events needed doctor or other healthcare professional office/clinic visit. Steroid (prednisone) was taken to reduce inflammation. Both events were not recovered. No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Body temperature abnormal, Fatigue, Gait disturbance, Headache
Clinical narrative: Slight headache; trouble walking; Tired.; Body temperature; This is a spontaneous report from a contactable consumer, the patient. A 66-year-old non pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA Vaccine; Lot number: EN6200,), via an unspecified route of administration in the left arm on 20Feb2021 at 09:00 (at the age of 66-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient had allergies to medications, food, or other products (details unspecified). The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA Vaccine; Lot number: EL9264), via an unspecified route of administration in the left arm on 30Jan2021 at 16:00 (at the age of 66-years-old) as a single dose for COVID-19 immunisation. Prior to vaccination, patient was not diagnosed with COVID-19. Since vaccination, patient has not tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 25Feb2021 at 07:00, the patient experienced slight headache, temperature 100.4 (unit unspecified), trouble walking, effected both knees and tired. The events resulted in doctor or other healthcare professional office/clinic visit. However, no therapeutic measures were taken as a result of the reported events. The clinical outcomes of the events slight headache, temperature 100.4 (unit unspecified), trouble walking, effected both knees and tired were recovering at the time of reporting.  No follow-up attempts are needed. No further information is expected.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Retching
Clinical narrative: Dry heaves; Chills; Headache; This is a spontaneous report from a contactable consumer. A 66-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: E90955) via an unspecified route of administration in the left arm, on 26Mar2021 at 11:00 (at the age of 66-year-old), as a single dose for COVID-19 immunisation. Medical history included allergy to sulfa (sulfonamide allergy). Concomitant medication was not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 26Feb2021 at 11:30 (at the age of 66-year-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On 28Mar2021 at 18:00, the patient experienced chills, dry heaves and headache. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported events. The clinical outcome of chills, dry heaves and headache were not recovered at the time of this report. No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pyrexia
Clinical narrative: body aches; High Fever; This is a spontaneous report from a contactable consumer. A 56-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: unknown), via an unspecified route of administration in the left arm on 26Mar2021 at 08:30 (at the age of 56-year-old), as a single dose for COVID-19 immunisation. The patient had no medical history reported. Concomitant medications included doxycycline (MANUFACTURER UNKNOWN) from an unknown date for unknown indication. The patient had no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccination. On 27Mar2021 at 12:00, the patient experienced body aches and high fever. The patient did not receive any treatment for the events. The events didn't result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events body aches and high fever was recovered on an unknown date at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Asthenia, Fatigue, Headache, Nausea
Clinical narrative: Felt very week,; following day, I got fever,; headache,; bodyache; joint pain,; nauseas.; after 3 hrs receiving vaccine got extremly tired.; Very sleepy, slept into the following day.; This is a spontaneous report received from a contactable consumer, the patient. A 46-year-old non-pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number:ER8732), via an unspecified route of administration in the left arm on 26Mar2021 at 13:45 (at the age of 46-year-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 on an unknown date. Concomitant medications were reported as none. The patient had no known allergies. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 26Mar2021 at 17:00, the patient experienced extremely tired, very sleepy, slept into the following day. On27Mar2021 patient experienced fever, headache, body ache, joint pain, nauseas, and on an unknown date felt very week and slept most of the day. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit. The patient took TYLENOL as treatment for the reported events. The clinical outcome of the events extreme fatigue, very sleepy, fever, headache, body ache, joint pain, nauseas and very weak was resolving at the time of the report.   No follow-up attempts are needed. No further information is expected.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pyrexia, Somnolence
Clinical narrative: Felt very week,; following day, I got fever,; headache,; bodyache; joint pain,; nauseas.; after 3 hrs receiving vaccine got extremly tired.; Very sleepy, slept into the following day.; This is a spontaneous report received from a contactable consumer, the patient. A 46-year-old non-pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number:ER8732), via an unspecified route of administration in the left arm on 26Mar2021 at 13:45 (at the age of 46-year-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 on an unknown date. Concomitant medications were reported as none. The patient had no known allergies. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 26Mar2021 at 17:00, the patient experienced extremely tired, very sleepy, slept into the following day. On27Mar2021 patient experienced fever, headache, body ache, joint pain, nauseas, and on an unknown date felt very week and slept most of the day. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit. The patient took TYLENOL as treatment for the reported events. The clinical outcome of the events extreme fatigue, very sleepy, fever, headache, body ache, joint pain, nauseas and very weak was resolving at the time of the report.   No follow-up attempts are needed. No further information is expected.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Oral herpes
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 61-years-old non-pregnant female patient received first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN) on 04Mar2021 (at the age of 61-years-old) as a single dose for COVID-19 immunization and received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via unspecified route of administration in the left arm on 24Mar2021 at 11:00 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. Medical history included obesity, mitral valve prolapse (MVP) and osteoarthritis. The patient did not have allergies to medications, food, or other products. Concomitant medications were not reported. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On an unknown date in Mar2021, after first vaccine the patient experienced cold sore - left side of tongue for a couple of days. On 25Mar2021 after Second vaccine, the patient experienced cold sore- right side of tongue for a couple of days. The adverse events did not result in doctor or other healthcare professional office/clinic visit. The patient did not receive treatment for the reported events. The clinical outcome of the events cold sore (after first vaccine) and after second vaccine was recovered on an unknown date in Mar2021. No follow-up attempts are needed; information about lot number cannot be obtained.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021357059 same patient/drug/event occurred in different place
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Nausea
Clinical narrative: Nausea all day; Very tired/unusually tired; This is a spontaneous report from a contactable consumer, the patient. A 69-year-old non pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN) via unspecified route of administration in left arm on 23Mar2021 at 16:00 (at the age of 69-years-old) as a single dose for COVID-19 immunisation. Medical history included arthritis and hypertension. The patient was allergic to penicillin. Concomitant medications included ibuprofen (MANUFACTURER UNKNOWN) and irbesartan (MANUFACTURER UNKNOWN) for unknown indication from unknown date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN), via unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient had not received any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 26Mar2021 (day 3), the patient experienced very tired, unusually tired. On 31Mar2021 at 08:00 (day 9), the patient experienced nausea all day. The patient had not received treatment for the adverse events. The clinical outcome of the events very tired and nausea were resolving at the time of this report.   No follow-up attempts are needed; information about lot number cannot be obtained.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Nasal congestion, SARS-CoV-2 test, Sneezing
Clinical narrative: sneezing often; very congested; This is a spontaneous report from a contactable consumer, the patient. A 30-years-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN), via an unspecified route of administration, in the left arm on 28Mar2021 at 18:00 (at the age of 30-year-old) as a single dose for COVID-19 immunisation. The patient had no medical history. Concomitant medication which the patient received within 2 weeks of vaccination included birth control and steroid taken for asthma from an unknown date. The patient had no allergies to medications, food, or other products. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was tested for COVID-19, which included nasal swab test on 11Mar2021 and resulted negative. On 29Mar2021 at 20:00 (24 hours after vaccine), the patient experienced very congested and sneezing often but the patient was not sure if this is related to the shot. Treatment was not received for adverse events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of events congested and sneezing often were resolving at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Pain in arm I received vaccine. Arm felt sore for about 2 days.; This is a spontaneous report from a contactable consumer, the patient. A 44-year-old non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown) via unspecified route of administration in the arm on 25Mar2021 at 11:00 (at the age of 44-years-old) as a single dose for Covid-19 immunisation.  Medical history and concomitant medication  was reported as no. The patient was allergic to peanuts.  The patient had not received any other vaccines within 4 weeks prior to the COVID vaccine. The patient was not diagnosed with COVID-19 prior to vaccination and since the vaccination, the patient had not been tested for COVID-19.The patient experienced pain in vaccinated arm  on 25Mar2021, and arm felt sore for about 2 days. The patient had not received any treatment for the reported event. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. The clinical outcome of the pain in arm was resolved.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Fatigue, Headache, Lip swelling, Pain
Clinical narrative: dizziness; achiness; Terrible headache; tiredness; swelling of lips, tongue; Itching all over; swelling of lips, tongue; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route administration in the left arm on 01Mar2021 at 14:00 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. Medical history included allergies to penicillin, cephalosporins and many other medications. Concomitant medications included routine unspecified allergy medicine and vitamins (MANUFACTURER UNKNOWN), for unknown indications from unknown dates. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 01Mar2021 at 14:00, the patient experienced terrible headache, achiness, tiredness and dizziness. On 01Mar2021, the patient experienced itching all over and swelling of lips, tongue which started roughly 7-8 minutes after injection. The patient was released after 30 minutes to go home and instructed to take diphenhydramine (BENADRYL). The patient had to use inhaler as well. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient received treatment with diphenhydramine (BENADRYL) and unspecified inhaler for the events itching all over and swelling of lips, tongue. The patient did not receive any treatment for events terrible headache, achiness, tiredness and dizziness. The clinical outcomes of the events headache, ache, tiredness, itching all over, dizziness, swelling of tongue and swelling of lips were recovered on an unknown date in Mar2021.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus, Swollen tongue
Clinical narrative: dizziness; achiness; Terrible headache; tiredness; swelling of lips, tongue; Itching all over; swelling of lips, tongue; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route administration in the left arm on 01Mar2021 at 14:00 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. Medical history included allergies to penicillin, cephalosporins and many other medications. Concomitant medications included routine unspecified allergy medicine and vitamins (MANUFACTURER UNKNOWN), for unknown indications from unknown dates. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 01Mar2021 at 14:00, the patient experienced terrible headache, achiness, tiredness and dizziness. On 01Mar2021, the patient experienced itching all over and swelling of lips, tongue which started roughly 7-8 minutes after injection. The patient was released after 30 minutes to go home and instructed to take diphenhydramine (BENADRYL). The patient had to use inhaler as well. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient received treatment with diphenhydramine (BENADRYL) and unspecified inhaler for the events itching all over and swelling of lips, tongue. The patient did not receive any treatment for events terrible headache, achiness, tiredness and dizziness. The clinical outcomes of the events headache, ache, tiredness, itching all over, dizziness, swelling of tongue and swelling of lips were recovered on an unknown date in Mar2021.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 48.0
Sex: M
Vaccine: COVID19
Symptoms: Dizziness, Feeling abnormal
Clinical narrative: sudden strong dizzy feeling while walking/ light headed feeling; felt off; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8730) via an unspecified route of administration in the left arm on 30Mar2021 at 12:30 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had no allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medications included eszopiclone (LUNESTA) 3mg and cetirizine hydrochloride (ZYRTEC) as OTC, daily night time. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 31Mar2021 at 20:30, the patient experienced sudden strong dizzy feeling while walking. It was reported that, the patient was cleared, felt off (feeling abnormal) and slightly light headed. Light headed feeling was persisting, slightly dizzy almost like the patient could become nauseous but not. Slightly dizzy was persisting. The adverse event did not result in doctor/other healthcare professional office or clinic visit/emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of event sudden strong dizzy feeling while walking/ light headed feeling was not resolved and felt off (feeling abnormal) was unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Burning sensation, Pruritus, Urticaria
Clinical narrative: annoying itchiness; skin hives with irregular shapes appearing on different location of body parts of skin at different times. Localized to left forehead, neck, both earlobes, back of trunk, both upper arm and both thigh areas; burning sensation of red spots/skin hives; This is a spontaneous report from a non-contactable consumer, the patient. A 63-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN 6207) via an unspecified route of administration in the left arm on 19Mar2021 at 12:30 (at the age of 63-years-old) as a single dose for COVID-19 immunisation. Medical history included seasonal allergies or allergic rhinitis. Any allergies to medications, food, or other products were reported as unknown. The patient received fosamax (MANUFACTURER UNKNOWN), multivitamins (MANUFACTURER UNKNOWN) and Calcium, Vitamin D supplements (MANUFACTURER UNKNOWN) within two weeks prior to vaccination. The patient had not received any other vaccines within four weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 19Mar2021 at 18:00, after 5:30 hours, the patient experienced burning sensation of red spots/skin hives and skin hives with irregular shapes appearing on different location of body parts of skin at different times. Localized to left forehead, neck, both earlobes, back of trunk, both upper arm and both thigh areas. Subsided after ingestion of anti-allergy medication; recurring intervals of the day throughout the week for 2 weeks. On 29Mar2021 patient had annoying itchiness at the time reporting. Therapeutic measures were taken as a result of hives, burning sensation and itching and included prednisone 10 mg orally after meals. The adverse events had resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of hives, burning sensation was not recovered and the clinical outcome of itching was unknown at the time of this report.    No follow-up attempts are needed. No further information is expected
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Blood pressure increased, Heart rate increased
Clinical narrative: Rapid heart rate; Elevated blood pressure; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number; ER2613) via an unspecified route of administration on 27Mar2021 at 16:00 (at the age of 52-year-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure. Concomitant medications included losartan potassium (MANUFACTURER UNKNOWN) from an unknown date and for an unknown indication. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 27Mar2021 at 16:00, the patient experienced rapid heart rate and elevated blood pressure. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported events. The clinical outcome of the events rapid heart rate and elevated blood pressure was resolved on an unknown date in Mar2021.   No follow-up attempts are needed. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Chest pain
Clinical narrative: chest pains; This is a spontaneous report from a contactable (patient). A female patient of an unspecified age received bnt162b2 (Pfizer-BioNTech COVID-19 Vaccine, Solution for injection), dose 1 via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as dose 1, single for covid-19 immunisation. The patient medical history was not reported. The patient's concomitant medications were not reported. Prior to taking the second dose of the Pfizer-BioNTech COVID-19 Vaccine, patient was having some chest pains and took Aspirin 30 minutes before the vaccine. Patient reported only to have a had a sore arm and felt a little unwell. The outcome of the event was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Blood pressure measurement, Body mass index, Dizziness, Hypotension
Clinical narrative: Took BP, was 85/65-stayed in that range for 2 hours- laid down.; extreme light-headedness; This is a spontaneous report from a contactable consumer, the patient. A 62-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the left arm on 28Mar2021 at 14:45 (at the age of 62-years-old) as a single dose for COVID-19 immunisation.  Medical history included spontaneous coronary artery dissection (SCAD), migraines, irritable bowel syndrome (IBS) and non-ST segment elevation myocardial infarction (N-STEMI). Concomitant medications included apixaban (ELIQUIS), rosuvastatin (MANUFACTURER UNKNOWN), metoprolol (MANUFACTURER UNKNOWN), cetirizine hydrochloride (ZYRTEC) and montelukast (MANUFACTURER UNKNOWN), all for unknown indications from unknown dates. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via an unspecified route of administration in the left arm on 07Mar2021 at 15:00 (at the age of 62-years-old) as a single dose for COVID-19 immunisation.  Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. It was reported that the patient was only on metoprolol as a preventive so as not have a second SCAD. The patient did not have hypertension and was on 50 mg two times a day. On 30Mar2021 at 18:45, after dinner, the patient had extreme light-headedness. The patient was not dehydrated and was not fasting. The patient's blood pressure (BP) was measured which stayed in the range 85/65 for 2 hours-laid down. The patient had never been hypotensive either. This happened 52 hours post second vaccine. On 31Mar2021 (reported as next day), she still felt moderately light headed, but BP was better, in 107/75 to113/85 range. The patient's body mass index (BMI) was 23.77 kg/m2. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event took BP, was 85/65-stayed in that range for 2 hours-laid down was resolving while that of extreme light-headedness was not resolved at the time of the report.    No follow-up attempts are needed. No further information is expected.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Diarrhoea, Gait inability, Headache, Nausea, Pyrexia
Clinical narrative: unspecified route of administration on an unknown date (at the age of 59-years-old) as a single dose for COVID-19 immunisation. Medical history included cancer 10 years ago. The patient did not have any known allergies. Concomitant medications included levothyroxine sodium (SYNTHROID) and venlafaxine hydrochloride (EFFEXOR) from unknown dates for unknown indications. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 15Mar2021 at 16:00, the patient experienced shaky, nausea, diarrhea, couldn't walk, headache  and fever. Therapeutic measures were taken as a result of  the events included treatment with TYLENOL ,ADVIL, ZOFRON and IMODIUM. The clinical outcomes of the events shaky, nausea, diarrhea, couldn't walk, headache, fever were not recovered at the time of the report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.